$189 a month for compounded semaglutide on Healthon's program page, and the same $189 on its product page footnoted as a twelve-month prepay. Both pages were read the same day.
KTKevin Turner, Reviews Editor · Prices read on the company's own pages · How we review
What it is
Healthon sells compounded semaglutide and tirzepatide through a Shopify storefront, describing itself in the footer of every page as "a patient management platform that works with independent licensed providers" rather than as a prescriber.
It is also the one company on this roster carrying a live FDA warning letter about the way it advertised these exact two molecules. The letter is disclosed in full below; it is a fact about the company's marketing on a date, not a ruling about what it sells today.
⚠ The same figure carries two incompatible footnotes on two Healthon pages read the same day. The program page prices semaglutide at "As low as $189/mo*" and footnotes it "*On a monthly plan." The product page prints "Starting at $189" and footnotes it "*Paid upfront with a 12-month plan." The rungs above follow the program page, because that page's own arithmetic only works if $189 is a monthly rate: its quarterly plan is $549, which is $183 a month, a small discount on $189 — and a quarterly rate cannot undercut a twelve-month prepay. ⛔ The product page's footnote is recorded as a contradiction, not resolved into agreement.
⚠ Tirzepatide carries two different monthly figures on the two pages, five dollars apart, both read on September 2, 2026: the program page says "As low as $295/mo*" and the product page says "Starting at $290". The program page's figure is recorded because it is the one whose footnote defines the term and whose quarterly rung — $837, or $279 a month — is arithmetically consistent with it.
$189 a month is the cheapest semaglutide plan on Healthon's program page, which footnotes it "On a monthly plan." Tirzepatide is $295 the same way. Commit to three months and semaglutide is $549 a quarter, which is $183 a month, and tirzepatide is $837, which is $279.
Then the problem: the semaglutide product page prints the same $189 and footnotes it "Paid upfront with a 12-month plan." Those two footnotes cannot both be true of one number, and the pages were read on the same day. The program page's own arithmetic is the reason its reading is recorded — a $549 quarter works out at $183 a month, and a quarterly rate that undercuts a twelve-month prepay is not a coherent ladder.
The same split hits tirzepatide differently: $295 a month on the program page, $290 on the product page. Both pages also advertise a checkout discount that is never priced on the page — "Up to $408 off your 12-Month Plan - Discount shown at checkout" for semaglutide, $375 for tirzepatide — so the figure a card is actually charged is not published anywhere a reader can read it before starting.
The full breakdown — what is included, what is extra, and what happens at higher doses — is on the Healthon cost page.
Who it's wrong for
Anyone who needs to know what they are committing to before they pay. Healthon's own two pages disagree about whether $189 buys a month or a year, and the plan screen that would settle it sits behind a checkout.
Anyone counting on the six-month money-back guarantee. It carries eight separate conditions, and one of them requires exercising 150 minutes a week and proving it through a smart watch linked to Healthon's records.
Anyone who wants a named pharmacy or a stated licensure. Across the six pages captured, no pharmacy is named, no statement says a prescriber is licensed in the patient's own state, and no support hours are published.
Anyone who wants a company with no regulatory history on this product. FDA wrote to Healthon in September 2025 about its compounded semaglutide and tirzepatide advertising; the four claims it quoted are gone from the pages read a year later, but the letter is part of the record.
The American checks
Prescriber licensed in your state
Not stated
Pharmacy named
Not named
What you get
Compounded semaglutide and tirzepatide, described as prepared by U.S.-licensed compounding pharmacies within the Healthon network
Overseas fulfillment
Not stated
Support hours
Not published
These are the checks this site applies to every company — how we review. Not stated means we could not find it on their site, which is a finding about the site, not about the company.
On the record11 sourcing notes — every price with the page it was read from, and what we could not find
Read September 2, 2026: six of Healthon's own pages as rendered text with disclosures expanded — the compounded semaglutide product page, the tirzepatide product page, the weight-loss program page, the terms of service, the cancellation policy and the money-back guarantee. An intake walk was started and stopped at the plan screen, which sits behind a Shopify selling plan.
★ The prices, quoted in reading order from the program page's plan list: "Semaglutide As low as $189/mo* *On a monthly plan.", "Tirzepatide As low as $295/mo* *On a monthly plan.", "Semaglutide Quarterly Plan $549/quarter* *On a 3-month plan." and "Tirzepatide Quarterly Plan $837/quarter* *On a 3-month plan." The page's own hero reads "Personalized doctor-led plans, as low as $189/mo".
★ The contradiction, quoted from the other page. https://healthon.com/products/compounded-semaglutide prints "Starting at $189" above the footnote "*Paid upfront with a 12-month plan. Actual price to the consumer will depend on the plan purchased." https://healthon.com/products/tirzepatide-1 prints "Starting at $290" above the identical footnote. Both were read the same day as the program page. Neither the terms of service, the cancellation policy nor the money-back guarantee names any figure, so the Embody rule — where a company's own legal documents settle what its marketing leaves ambiguous — has nothing to work with here.
The checkout discounts, which are advertised and never priced on the page: "Up to $408 off your 12-Month Plan - Discount shown at checkout" on the semaglutide page and "Up to $375 off your 12-Month Plan - Discount shown at checkout" on the tirzepatide page.
⚖ FDA WARNING LETTER 719809, issued September 9, 2025, to "Healthon Inc. dba Healthon", 100 Spectrum Center Dr #900, Irvine, CA 92618, addressed to Dr. Rasoul M. Montazeri, M.D., Founder & Chief Executive Officer, at hello@healthon.com. ⛔ ATTRIBUTED ON ENTITY AND ADDRESS, NOT ON A NAME: the address on the letter is character for character the address Healthon publishes in its own terms of service, "100 Spectrum Center Dr #900, Irvine, CA 92618". The letter was fetched from FDA's own site on September 3, 2026 with a control in the same run — Strut Health 721448 returned its own distinct address, 701 Commerce St, Dallas, TX, and a nonsense letter path on the same host returned 404, so the fetch discriminates.
What the letter actually says, because the index's category line is broader than the letter's substance. FDA reviewed healthon.com in August 2025 and objected to four advertising claims, quoted in the letter: "Same active ingredient as Wegovy and Ozempic.", "Same active ingredient as Mounjaro pens and Zepbound.", "Clinically proven weight loss" and "The active ingredient in our formula is FDA-approved…." Its finding is that these are false or misleading under sections 502(a) and 502(bb) of the FDCA because they imply a compounded product is the same as an FDA-approved one. It is a misbranding letter about advertising; it makes no finding about the medication's contents, the pharmacy, or patient harm.
None of the four quoted claims appears on any of the six Healthon pages captured on September 2, 2026 — a census of those six pages, not of the whole site. What the pages carry instead is the opposite disclosure, twice: "This medication is compounded and has not been evaluated or approved by the FDA for safety or effectiveness" on both product pages, and "Please note: Compounded medications are not reviewed or approved by the FDA for safety or effectiveness" on the program page.
⚖ A warning letter discloses; it does not disqualify. That is a standing owner ruling for this network, and it is why Healthon carries a review and a full ladder rather than a refusal. Nothing in this record gates the listing or a link on the letter's existence.
The six-month money-back guarantee, and its eight conditions, from https://healthon.com/pages/money-back-guarantee: enrollment after August 25th 2024; at least 180 days as an active participant; medical forms and lab work uploaded within five days of joining; medication taken every week as prescribed with no refill requests in the sixth month; weight logged weekly in Healthie; less than 5% of starting body weight lost, from an initial BMI of 30 or above; and "Exercise 150 minutes per week, and provide proof via smart apps or smart watches linked to our EMR system." Returning members, members who cancel before 180 days, and members who joined before August 25th 2024 are excluded.
The same page opens with a weight-loss outcome claim, recorded here as the company's words and not repeated as a finding: "Lose 10.4% Body Weight in 6 Months with Semaglutide or Tirzepatide" and "Healthon members using Semaglutide or Tirzepatide typically achieve a remarkable 10.4% reduction in body weight within just six months". This site does not publish weight-loss outcome claims.
Not stated, and searched for. Across the six pages captured, no compounding pharmacy is named — the terms speak only of "a pharmacy", "the pharmacy" and "the selected pharmacy" — nothing states that a prescriber is licensed in the patient's own state, nothing addresses where medication is compounded beyond "U.S.-licensed compounding pharmacies within the Healthon network", and no support hours are published. Those four rows read not stated for that reason.
What Healthon sells, priced across the market
The same molecules at every other company we have reviewed, with the range each one falls in.